Refractory Lymphoma
Showing NaN - NaN of 19
Brain Stem Tumor, Pineal Region Tumor, Recurrent Lymphoma Trial in United States (Entinostat, Laboratory Biomarker Analysis,
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma Trial in United States (Elimusertib)
Recruiting
- Recurrent Alveolar Rhabdomyosarcoma
- +7 more
-
Birmingham, Alabama
- +28 more
Jan 26, 2023
Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan,
Active, not recruiting
- Recurrent Lymphoma
- +5 more
- Irinotecan
- +2 more
-
Birmingham, Alabama
- +19 more
Oct 20, 2022
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,
Withdrawn
- Constitutional Mismatch Repair Deficiency Syndrome
- +11 more
- Biospecimen Collection
- +2 more
-
Palo Alto, California
- +8 more
Sep 9, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +37 more
-
Birmingham, Alabama
- +171 more
Aug 24, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Trametinib Dimethyl Sulfoxide
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 13, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Biopsy
- +3 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 5, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial
Active, not recruiting
- Diffuse Midline Glioma, H3 K27M-Mutant
- +10 more
- FACT Complex-targeting Curaxin CBL0137
-
Birmingham, Alabama
- +19 more
Jun 29, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Afatinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Afatinib Dimaleate
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Defactinib Hydrochloride
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor
Completed
- Advanced Lymphoma
- +5 more
- FGFR Inhibitor AZD4547
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 8, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Nivolumab)
Completed
- Advanced Lymphoma
- +5 more
- Nivolumab
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Mar 15, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Dasatinib)
Withdrawn
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jul 17, 2020